Abstract: A catheter device that includes a conduit having an outer wall, an internal lumen, and proximal and distal ends. The conduit further includes first and second pluralities of electrical conduits embedded in the outer wall of the conduit, which are adapted to transmit electrical current therethrough in a first direction and an opposing second direction. The conduit is adapted to transition from a pre-collapsed state to a first collapsed state when the first plurality of electrical conduits transmits a first electrical current in a first direction and the second plurality of electrical conduits transmits a second electrical current in a second direction, and transition from the first collapsed state to a second expanded state when the first plurality of electrical conduits and the second plurality of electrical conduits transmit a third electrical current in the first direction.

Abstract: A clot removal device for removal of an occlusion from a lumen in a patient's body is provided. The clot removal device has a lumen, an elongated member positioned within the lumen and extending axially from a proximal end to a distal end of the lumen, a handle attached to the proximal end of the lumen, a first expandable member positioned along a length of the elongated member, a second expandable member positioned along the length of the elongated member, wherein the second expandable member is distal to the first expandable member relative to the handle.

Abstract: In various embodiments, the present specification discloses an aspiration catheter that has a slim profile, can effectively anchor or self-center in a location, within a patient's vessel lumen, to better provide directed suction or vacuum/negative pressure, and/or can effectively funnel or direct suction or vacuum/negative pressure toward an occlusion or obstruction within the patient's vessel lumen.

Abstract: A device is disclosed for occluding an anatomical passage between first and second anatomical structures. The device includes a tip portion having a proximal element connected to a distal element through a member. The proximal element and/or distal element is movable axially along the tip portion while the other element preferably remains fixed in place. A handle is coupled to a proximal end of the tip portion through a shaft. The tip portion is positioned across the anatomical passage so that the proximal element occludes a first side of the passage and the distal element occludes a second side of the passage. A locking structure, such as a nut, is positioned or crimped against the proximal element, and, once done, the tip portion is released at the occluded passage.

Abstract: A clot removal device for removal of an occlusion from a lumen in a patient's body is provided. The clot removal device has a lumen, an elongated member positioned within the lumen and extending axially from a proximal end to a distal end of the lumen, a handle attached to the proximal end of the lumen, a first expandable member positioned along a length of the elongated member, a second expandable member positioned along the length of the elongated member, wherein the second expandable member is distal to the first expandable member relative to the handle.

Abstract: of treating Gram-negative bacteria that also exhibit resistance to the anti-bacterial compound colistin (MIC?50 mg/mL) except for Burkholderia, Proteus, and Serratia that comprises contacting the bacteria with an aqueous pharmaceutical composition containing a rose bengal (RB) compound of Formula I, below, dissolved or dispersed therein at a concentration of about 0.01 to about 15 mg/mL and irradiating those contacted bacteria with light of the wavelength about 500 nm to about 600 nm for a time period of about 1 to about 10 minutes to provide a light dose of about 16 to about 160 J/cm2, treat and kill the irradiated bacteria wherein X, R1, R2 and M+ are defined within.

Abstract: A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the Type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene, and an immunogen to which that response is to be enhanced. A mammalian HX compound-adjuvanted vaccine composition that contains an immunogen present in a vaccine-effective amount along with an adjuvant-effective amount of a halogenated xanthene (HX) compound and one or more excipients present at about 0.001% by weight to 10% by weight of the vaccine composition dissolved or dispersed in a pharmaceutically acceptable diluent.

Abstract: A blood reinfusion system for processing autologous blood for reinfusion into a patient. The system includes a blood reinfusion system having a blood processing canister with an internal fluid passageway. The internal fluid passageway includes a venturi region having a gravity-driven filtering system that is adapted to extract impurities from autologous blood without damaging the erythrocytes in the blood and, hence, inducing hemolysis of the erythrocytes in the blood, and loss of seminal native blood components, including native erythrocytes, platelets, white blood cells, plasma proteins and antibodies.

Abstract: A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.

Abstract: A method for treating a viral infection of a mammalian subject that comprises administering a virus-inhibiting amount of a halogenated xanthene, a pharmaceutically acceptable salt, an alkyl ester or amide or aromatic ester or amide derivative thereof as disclosed within, to that mammalian subject. A method of inducing a type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene as discussed above, and an immunogen to which that response is to be enhanced.

Abstract: A blood reinfusion system for processing autologous blood for reinfusion into a patient. The system includes a suction container adapted to receive a mixture of autologous blood and impurities and extract the impurities from the mixture, a blood filter assembly adapted to further extract the impurities from the mixture, whereby whole purified autologous blood is obtained, and a blood transfer bag adapted to receive the whole purified autologous blood from the blood filter assembly.

Abstract: A method for processing autologous blood for reinfusion into a patient. The method includes the step of providing a blood reinfusion system adapted to isolate and extract impurities mixed with autologous blood aspirated from an incision site of the patient for reinfusion into the subject.

Abstract: A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the Type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene, and an immunogen to which that response is to be enhanced. A mammalian HX compound-adjuvanted vaccine composition that contains an immunogen present in a vaccine-effective amount along with an adjuvant-effective amount of a halogenated xanthene (HX) compound and one or more excipients present at about 0.001% by weight to 10% by weight of the vaccine composition dissolved or dispersed in a pharmaceutically acceptable diluent.

Abstract: The present invention contemplates a topical ophthalmic system for treating a Gram-positive bacterially-infected mammalian eye. The system comprises an ophthalmic composition containing a halogenated fluorescein or a pharmaceutically acceptable salt or ester thereof dissolved or dispersed in an aqueous ophthalmic carrier and present in an anti-bacterial keratitis-treating effective concentration of about 0.2 µg/mL to about 50 µg/mL. The ophthalmic composition has a pH value of about 6.5 to about 7.6, a viscosity of about 10 to about 300 cps and an osmolality of about 270 mOsm/kg to about 340 mOsm/kg. The ophthalmic composition is present in a vessel opaque to actinic light. Also contemplated is a method of treating a mammal having a Gram-positive bacterial infection of an eye by administering the ophthalmic composition to the infected eye and maintaining the treated eye in the substantial absence of actinic light for about 3 hours to about 12 hours.

Abstract: This invention contemplates combined use of a rose bengal (RB) derivative with irradiation of bacteria with light to treat and kill the irradiated bacteria. In one aspect, Gram-positive bacteria are treated in a method in which the bacteria are contacted with an aqueous pharmaceutical composition containing a rose bengal (RB) compound of Formula I, discussed within, dissolved or dispersed therein at about 0.2 to about 3.1 µg/mL. Those contacted bacteria are contacted with light of the wavelength about 500 nm to about 600 nm for a time period of about 1 to about 10 minutes to provide a light dose of about 0.7 to about 7.2 J/cm2. A similar method is contemplated for treating Gram-negative bacteria that are one or more of Burkholderia, Salmonella, and Proteus using an aqueous pharmaceutical composition containing about 2 to about 15 µM concentration of the RB compound.

Abstract: Provided herein are methods and systems for the removal of anatomical occlusions, and an occlusion removal device comprising a first body adapted to be mounted to a delivery wire and releasably engaged to the delivery wire, wherein while engaged the first body remains fixed on the delivery wire and upon release moves axially along the delivery wire, and a second body adapted to be mounted to the delivery wire. A first proximal body may be oriented proximally to a second distal body. The proximal body and the distal body may be adapted to expand upon exiting a delivery catheter. The proximal body may be releasably engaged by a mechanically breakable connection or an electrolytically or heat disconnectable connection, the electrolytically disconnectable connection being broken upon an application of electric current to the electrolytically disconnectable connection.

Abstract: A clot removal device for removal of an occlusion from a lumen in a patient's body is provided. The clot removal device has a lumen, an elongated member positioned within the lumen and extending axially from a proximal end to a distal end of the lumen, a handle attached to the proximal end of the lumen, a first expandable member positioned along a length of the elongated member, a second expandable member positioned along the length of the elongated member, wherein the second expandable member is distal to the first expandable member relative to the handle.

Abstract: A clot removal device for removal of an occlusion from a lumen in a patient's body is provided. The clot removal device has a lumen, an elongated member positioned within the lumen and extending axially from a proximal end to a distal end of the lumen, a handle attached to the proximal end of the lumen, a first expandable member positioned along a length of the elongated member, a second expandable member positioned along the length of the elongated member, wherein the second expandable member is distal to the first expandable member relative to the handle.

Abstract: Provided herein are methods and systems for the removal of anatomical occlusions, and an occlusion removal device comprising a first body adapted to be mounted to a delivery wire and releasably engaged to the delivery wire, wherein while engaged the first body remains fixed on the delivery wire and upon release moves axially along the delivery wire, and a second body adapted to be mounted to the delivery wire. A first proximal body may be oriented proximally to a second distal body. The proximal body and the distal body may be adapted to expand upon exiting a delivery catheter. The proximal body may be releasably engaged by a mechanically breakable connection or an electrolytically or heat disconnectable connection, the electrolytically disconnectable connection being broken upon an application of electric current to the electrolytically disconnectable connection.

Abstract: A device is disclosed for occluding an anatomical passage between first and second anatomical structures. The device includes a tip portion having a proximal element connected to a distal element through a member. The proximal element and/or distal element is movable axially along the tip portion while the other element preferably remains fixed in place. A handle is coupled to a proximal end of the tip portion through a shaft. The tip portion is positioned across the anatomical passage so that the proximal element occludes a first side of the passage and the distal element occludes a second side of the passage. A locking structure, such as a nut, is positioned or crimped against the proximal element, and, once done, the tip portion is released at the occluded passage.